olprinone has been researched along with cyclic gmp in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fujikawa, H; Kanno, T; Nagata, T; Nishizaki, T | 1 |
| Hatano, Y; Kimoto, Y; Minonishi, T; Negoro, T; Ogawa, K; Tokinaga, Y | 1 |
2 other study(ies) available for olprinone and cyclic gmp
| Article | Year |
|---|---|
The phosphodiesterase III inhibitor olprinone inhibits hippocampal glutamate release via a cGMP/PKG pathway.
Topics: Animals; Calcium; Carbazoles; Cyclic GMP; Cyclic GMP-Dependent Protein Kinases; Excitatory Postsynaptic Potentials; Glutamic Acid; Hippocampus; Imidazoles; In Vitro Techniques; Isoquinolines; Male; Membrane Potentials; Phosphodiesterase 3 Inhibitors; Phosphodiesterase Inhibitors; Potassium; Protein Kinase Inhibitors; Pyramidal Cells; Pyridones; Rats; Rats, Wistar; Receptors, AMPA; Signal Transduction; Sulfonamides | 2008 |
Differential vasodilation response to olprinone in rabbit renal and common carotid arteries.
Topics: Animals; Carotid Artery, Common; Cyclic AMP; Cyclic GMP; Cyclic Nucleotide Phosphodiesterases, Type 3; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclic Nucleotide Phosphodiesterases, Type 5; Dose-Response Relationship, Drug; Imidazoles; In Vitro Techniques; Isoenzymes; Male; Muscle, Smooth, Vascular; Organ Specificity; Phosphodiesterase 3 Inhibitors; Phosphodiesterase Inhibitors; Pyridones; Rabbits; Random Allocation; Renal Artery; Vasoconstriction; Vasodilation; Vasodilator Agents | 2010 |